Ann: Results of Major Clinical Study-Genera Biosy, page-11

re: Ann: Results of Major Clinical Study-Gene... Yes I agree that an outright call that PapType is a superior test to HC2 may be drawing a long bow.

That said I think we all agree that the data on a comparable basis is solid and subject to more favourable data (and specifically from a screening population) GBI looks well positioned to have an attractive HPV test on its hands.

I will look to the calibre (and the terms) of the partner to be signed up in getting a lot more comfort from a due diligence perspective.

At 69c with a market cap of A$40m, IMO it wont take much to see all holders generate a very nice return on this one.

I imagine that the false positives et al will be disclosed in their broker roadshow material. Cervista generated false positives of 55-57% in its screening study under which it received FDA approval. I imagine PapType and HC2 should be under this as this trial was from ASCUS subjects who appear to have had a very high disease prevalence.